B-cell marker expression in acute myeloid leukemia with plasmacytoid dendritic cell differentiation (pDC-AML) without RUNX1 lesions: An underrecognized diagnostic pitfall.

Giby V George, Neel V Hegde, Hong Fang, Fatima Zahra Jelloul, L Jeffrey Medeiros, Wei Wang, Siba El Hussein

Abstract read

In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Giby V GeorgeDepartment of Pathology, University of Pennsylvania, Philadelphia, PA, USA.

Neel V HegdeDepartment of Pathology, University of Vermont Larner College of Medicine, Burlington, VT, USA.

Hong FangDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Fatima Zahra JelloulDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

L Jeffrey MedeirosDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Wei WangDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Siba El HusseinDepartment of Pathology, University of Vermont Larner College of Medicine, Burlington, VT, USA. elhusseinsiba@gmail.com.ORCID http://orcid.org/0000-0002-1338-7107

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The co-expression of myeloid and B-cell antigens is characteristic of mixed-phenotype acute leukemia (MPAL)-B/myeloid. This finding can also be observed in AML with t(8;21)(q22;q22)/RUNX1::RUNX1T1, as well as in cases of AML with other RUNX1 rearrangements, copy number gains, or mutations. AML with plasmacytoid dendritic cell (pDC) differentiation (pDC-AML) containing clonally-related myeloblasts and neoplastic pDCs, are enriched for RUNX1 mutations and have been shown to exhibit B-cell marker expression. Here, we present two cases of pDC-AML with B-cell marker expression in which RUNX1 aberrations were not identified. Although previously we speculated on the role of RUNX1 in the aberrant expression of B-cell markers such in cases, the absence of RUNX1 lesions in the current cases supports the potential inherent ability of pDCs to express B-cell markers during maturation.

Indexed as

Acute myeloid leukemiaAMLpDC-AMLPlasmacytoid dendritic cell differentiationRUNX1 mutation

Identifiers

PMID41582188

DOI10.3390/cancers13040764

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.